Interest is alsoincreasing in expanding testing for somatic mutations in ovarian cancer,particularly for genes such as BRCA1 and BRCA2, wherebymutations may allow more patients to benefit from targeted agents, includingpoly(ADP-ribose) polymerase inhibitors. This evidence concerns the gene BRCA2 and ovarian cancer.